The Society for Immunotherapy of Cancer (SITC) Immunoscore Validation Project is a global, collaborative effort (click here to view map) to introduce immune parameters into tumor classification systems. SITC played a critical role in facilitating communication and data transfer among all of the participating centers in this study (click here to view our process). Organized in collaboration with the European Academy of Tumor Immunology, the Cancer and Inflammation Program, the National Cancer Institute, National Institutes of Health, USA, and La Fondazione Melanoma, Italy.SITC Immunoscore Validation Project publishes findings in The Lancet.Published on May 10, 2018: "International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study” – featuring data from more than 3,500 colon cancer patients from 13 countries – reinforces earlier research suggesting the activity in a patient's immune system helps control cancer progression.
Outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical removal of a primary tumor, and focusing on the histopathological characteristics. Tumor staging (AJCC/UICC-TNM classification) is based on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N), and evidence of metastases (M). However, cancer outcomes can differ significantly between patients whose cancers are at the same stage. The TNM classification provides limited prognostic information in cancer and does not predict response to therapy.Increasingly, data suggest that cancer development is controlled by the host’s immune system, underlying the importance of including immunological biomarkers in the determination of prognosis and response to therapy, a concept that has been termed, “Immunoscore.” Data collected from human cancer tissue samples demonstrate that immune classification has prognostic value and may be a useful supplement to the AJCC/UICC TNM-classification. It is therefore important to begin incorporating immune scoring in determinations of cancer prognosis, and to make sure it becomes a routine part of the diagnostic and prognostic assessment of patients with cancer.
Published on May 10, 2018: "International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study” – featuring data from more than 3,500 colon cancer patients from 13 countries – reinforces earlier research suggesting the activity in a patient's immune system helps control cancer progression.Click here to view the study.
The latest results from the Immunoscore Validation Project were presented by Dr. Jérôme Galon during the Oral Abstract Session at the 2016 ASCO Annual Meeting. Click here to view the SITC press release and updated results.
Melanoma Bridge 2015Dec. 1-4, 2015 - Naples, ItalyWorld-Wide Immunoscore Task Force: An UpdateClick here for more informationImmunoscore Update Session at the SITC 30th Annual Meeting Nov. 7, 2015 – National Harbor, MD View video and presentation slides from this program here.Immunoscore Slide Sharing Portal Kick-off Call and PathForceDx Online Training Session Aug. 13, 2014 Participating Centers from across Europe, Asia, and North America met online to explore PathForceDx software functions and to discuss ideas and best practices for sharing slides and data.Natural and Therapy-induced Anticancer Immunosurveillance: The Immunoscore July 3-4, 2014 – Paris, FranceUpdates on Immunotherapy of Cancer and Immunoscore Jan. 23-24, 2014 – Doha, Qatar View abstracts published in JITC hereWorld Immunoscoring Meeting Dec. 4, 2012 – Naples, Italy Supported by SITC, Melanoma Foundation and EATI
Bernard A. Fox, PhDEarle A. Chiles Research Institute
Paolo Ascierto, MDInstituto Nazionale Tumori-Fondazione 'G. Pascale'Carlo Bifulco, MDProvidence Portland Medical CenterJérôme Galon, PhDUniversite Pierre Et Marie Curie, Sorbonne UniversitesFrancesco Marincola, MDRefuge Biotechnologies
Jérôme Galon, PhDINSERM, Cordeliers Research Center - Paris, France
Franck Pagès, MD, PhDImmunomonitoring plateform, Georges Pompidou European Hospital - Paris, France INSERM, Cordeliers Research Center - Paris, France
This initiative has been made possible with the generous support of the following companies:
Slide-sharing portal powered by PathForceDX
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org